Merck to present broad oncology advances at ASCO 2025

15 May 2025

New Jersey, USA-based cancer giant Merck & Co (NYSE: MRK) has announced it will unveil a comprehensive slate of new research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 in Chicago.

The company will present findings across more than 25 cancer types, highlighting both investigational therapies and long-term data on established medicines.

Among the key highlights, Merck will share new and updated results for MK-1084, an investigational KRAS G12C inhibitor. Data from the Phase I KANDLELIT-001 study will be presented for both colorectal cancer and non-small cell lung cancer (NSCLC) cohorts, focusing on patients with KRAS G12C-mutated advanced disease. These results will cover MK-1084 as a standalone therapy and in combination with other treatments, reflecting Merck’s ongoing efforts to address challenging mutations in solid tumors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK